Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 12/20 | 0.61 |
| ▸ | ACE | P12821 | 9/20 | 0.60 |
| ▸ | ACE2 | Q9BYF1 | 9/20 | 0.60 |
| ▸ | CPA1 | P15085 | 8/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24764799 | 1.00 | MME (0.61) | MMEACEACE2CPA1NPSR1 | |
| SCHEMBL6935193 | 0.90 | MME (0.66) | MMEACEACE2CPA1 | |
| SCHEMBL2622217 | 0.89 | NPSR1 (0.55) | MMEACEACE2CPA1NPSR1 | |
| SCHEMBL9223334 | 0.89 | NPSR1 (0.55) | MMEACEACE2CPA1NPSR1 | |
| SCHEMBL1061398 | 0.89 | NPSR1 (0.55) | MMEACEACE2CPA1NPSR1 | |
| SCHEMBL24766200 | 0.88 | MME (0.64) | MMEACEACE2CPA1 | |
| Hydrochloric Acid SCHEMBL902285 | 0.87 | NPSR1 (0.54) | MMEACEACE2CPA1NPSR1 | |
| Hydrochloric Acid SCHEMBL427903 | 0.87 | NPSR1 (0.54) | MMEACEACE2CPA1NPSR1 | |
| SCHEMBL24766216 | 0.85 | GNPAT (0.60) | — | |
| SCHEMBL9697077 | 0.83 | ACE (0.58) | MMEACEACE2CPA1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | MME 105/4885ACE 486/4885ACE2 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.